DOCETAXEL INDUCED PNEUMONITIS IN PATIENTS WITH METASTATIC PROSTATE CANCER

被引：0
|
作者：
Arasaratnam, Malmaruha [1 ]
Crumbaker, Megan [2 ]
Boys, Emma L. [1 ]
Gao, Bo [1 ]
Gurney, Howard [1 ,3 ]
机构：
[1] Westmead Hosp, Crown Princess Mary Canc Ctr, Med Oncol, Sydney, NSW, Australia
[2] Kinghord Canc Ctr, Med Oncol, Sydney, NSW, Australia
[3] Macquarie Univ, Med Oncol, Sydney, NSW, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
100
引用
收藏
页码：40 / 40
页数：1
相关论文
共 50 条
  • [41] Implications of metastatic stage at presentation in docetaxel naive metastatic castrate resistant prostate cancer
    Malone, Shawn
    Wallis, Christopher
    Morgan, Scott
    Kishan, Amar
    Le, Amy Tu Trinh
    Malone, Julia
    Sun, Yilun
    Spratt, Daniel
    Saad, Fred
    Roy, Soumyajit
    CANCER RESEARCH, 2023, 83 (07)
  • [42] Implications of metastatic stage at presentation in docetaxel naive metastatic castrate resistant prostate cancer
    Roy, Soumyajit
    Wallis, Christopher J. D.
    Morgan, Scott C.
    Kishan, Amar U.
    Le, Amy Tu Trinh
    Malone, Julia
    Sun, Yilun
    Spratt, Daniel E.
    Saad, Fred
    Malone, Shawn
    PROSTATE, 2023, 83 (10): : 912 - 921
  • [43] Clinical Activity of Enzalutamide in Docetaxel-Naive and Docetaxel-Pretreated Patients With Metastatic Castration-Resistant Prostate Cancer
    Nadal, Rosa
    Zhang, Zhe
    Rahman, Hibba
    Schweizer, Michael T.
    Denmeade, Samuel R.
    Paller, Channing J.
    Carducci, Michael A.
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    PROSTATE, 2014, 74 (15): : 1560 - 1568
  • [44] Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel
    Petrioli, Roberto
    Pascucci, Alessandra
    Francini, Edoardo
    Marsili, Stefania
    Sciandivasci, Angela
    De Rubertis, Giovanni
    Barbanti, Gabriele
    Manganelli, Antonio
    Salvestrini, Francesco
    Francini, Guido
    BJU INTERNATIONAL, 2007, 100 (04) : 775 - 779
  • [45] The timing of docetaxel initiation in metastatic castrate sensitive prostate cancer and the rate of chemotherapy induced toxicity.
    Kushnir, Igal
    Koczka, Kim
    Ong, Michael
    Canil, Christina M.
    Sabri, Elham
    Reaume, M. Neil
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer
    Hammerer, P.
    Manka, L.
    UROLOGE, 2019, 58 (10): : 1185 - 1197
  • [47] Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
    Kartolo, Adi
    Tannock, Ian F.
    Badillo, Francisco E. Vera
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3573 - +
  • [48] Cabazitaxel for metastatic hormone-relapsed prostate cancer treated with docetaxel
    Lovett, Rosemary
    Kelly, Victoria
    Goodall, Melinda
    Adler, Amanda I.
    LANCET ONCOLOGY, 2016, 17 (07): : 872 - 873
  • [49] Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC).
    Gernone, A.
    Pagliarulo, A.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer
    Gyawali, Bishal
    Koomulli-Parambil, Sahadudheen
    Iddawela, Mahesh
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 102 : 118 - 124
12345